NCT02866344

Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases

Prospective Randomized Comparison of Resection and Microwave Ablation for Resectable Colorectal Cancer Liver Metastases

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This single-center, prospective, randomized clinical trial is designed to compare the clinical characteristics and outcomes of hepatic resection and microwave ablation (MWA) to determine the optimal operative intervention for the local treatment of resectable colorectal cancer liver metastases. The primary aim of this study is to test the following hypothesis: 2-year local disease control is equivalent between patients receiving the experimental therapy (MWA) and patients receiving the standard therapy (hepatic resection) as treatment for colorectal cancer liver metastases determined to be resectable by radiographic imaging. Secondarily, the investigators expect that 2-year intrahepatic (regional) and metastatic disease recurrence rates are equivalent between the two treatment arms in this study.

Conditions

• Colorectal Neoplasms
• Neoplasm Metastasis
• Hepatic Neoplasms

Interventions

Type	Name	Description
PROCEDURE	Microwave ablation	Laparoscopic or robot-assisted laparoscopic microwave ablation of cancerous lesions with a 2.45-GHz microwave generator and a 1.8-mm-diameter transcutaneous antenna.
PROCEDURE	Hepatic resection	Laparoscopic or robot-assisted laparoscopic surgical resection of cancerous lesions.

Timeline

• Start date: 2016-08-01
• Primary completion: 2018-02-01
• Completion: 2018-02-01
• First posted: 2016-08-15
• Last updated: 2022-04-26

Locations

1 site across 1 country: United States